Skip to main content

Table 1 Characteristics of excluded studies

From: Dzherelo (Immunoxel) as adjunctive therapy to standard antituberculosis treatment in patients with pulmonary tuberculosis: a systematic review and meta-analysis of clinical trials

Study Reason for exclusion
Amin [4] This was a review [4]
Zulkifli et al. [17] Study was a systematic review [17]
Butov et al. [18] Study used V-5 Immunitor, an intervention not under this review [18]
Nikolaeva et al. [19] The study did not report of the outcomes of interest [19]
Nikolaeva et al. [19] This study [20] was duplicate of study [19]
Nikolaeva et al. [19] The study did not report any of the outcomes of interest, the study looked particularly at the effect of Dzherelo on immunological and virological responses (T-lymphocyte and viral load among TB/HIV patients) [20].
Prihoda et al. [21] Not a comparative study, in addition, all the participants received the intervention in combination with some other immunomodulators [21].
Prihoda et al. [22] The study compared Dzherelo (Immunoxel) with other forms of immunotherapies (Svitanok and Lizorm) [22].
Prihoda et al. [23] This study [23] was a duplicate of study [21].